What a whole body MRI actually is
A whole body MRI scan in Dehradun images the body from the skull base to the mid-thighs in a single appointment. Because a magnet only images a limited volume at a time, the study is acquired as a series of overlapping stations: the table steps through the bore and each segment is scanned in turn, then the segments are stitched into a continuous set of images.
The core sequences are a coronal or axial T1 and T2 for anatomy, plus diffusion-weighted whole body imaging with background suppression. That last one is the workhorse. It suppresses signal from normal tissue and highlights areas where water movement is restricted — which is characteristic of densely packed cells, such as tumour deposits and infiltrated bone marrow. The resulting inverted images look strikingly like a PET scan, with lesions appearing as dark foci against a pale background, and they are read in much the same way.
The single defining advantage is that all of this happens with zero ionising radiation. A whole body CT delivers a meaningful dose. A PET-CT delivers both a tracer dose and a CT dose. A whole body MRI delivers nothing, which is what makes repeated surveillance imaging feasible in young patients and in people who will need scanning every year for decades.
Two very different things share this name
This distinction causes more confusion than anything else on this topic, so it is worth being explicit.
Screening whole body MRI
Ordered by an individual, usually without symptoms, who wants a broad look for undetected disease. Protocol is a survey: reasonable coverage, moderate resolution, no contrast, roughly an hour.
Useful in the right person. Genuinely problematic in the wrong one — see the incidental findings section below.
Oncology whole body MRI
Ordered by an oncologist or haematologist for a specific clinical question: staging multiple myeloma, surveying for bone metastases in prostate or breast cancer, assessing lymphoma, or monitoring treatment response.
Protocol is targeted, often longer, and interpreted against defined reporting criteria such as MY-RADS or MET-RADS. This is established, evidence-backed practice.
What whole body MRI detects well
- Bone marrow disease. This is its strongest suit. Multiple myeloma, marrow infiltration and skeletal metastases are visible on diffusion imaging well before they cause the bone destruction that shows on X-ray or CT.
- Skeletal metastases in prostate and breast cancer. Comparable or superior to a bone scan, with the advantage of showing the soft tissue at the same time.
- Solid organ lesions. Liver, kidney, pancreas, spleen and adrenal masses are well characterised, with MRI outperforming CT for small liver lesions.
- Brain and spinal cord. Included in the coverage and imaged with the modality of choice for both.
- Lymphadenopathy. Enlarged nodes in the neck, chest, abdomen and pelvis.
- Aortic aneurysm and large vessel disease. Incidentally but reliably.
- Musculoskeletal pathology. Avascular necrosis, occult fractures, soft tissue masses.
What it misses — please read this part
A responsible centre tells you the limitations before you pay, not afterwards. Whole body MRI is not a universal cancer detector, and marketing that suggests otherwise is doing patients a disservice.
A normal whole body MRI does not mean you are cancer-free
- Small lung nodules. Lung is mostly air and contains little water, so MRI signal there is poor. Low-dose CT is the correct lung screening test.
- Early mucosal cancers. Stomach, colon, oesophagus, cervix and bladder cancers begin on a surface lining that MRI cannot resolve at this scale. Endoscopy, colonoscopy and cervical screening remain necessary.
- Breast cancer. Whole body protocols are not dedicated breast MRI. Mammography and dedicated breast imaging are not replaced.
- Prostate cancer detection. A whole body study is not a multiparametric prostate MRI and will not give a PI-RADS score.
- Coronary artery disease. Not assessed at all. That needs a CT coronary angiogram or functional cardiac testing.
- Below mid-thigh. Standard coverage stops there; the lower legs and feet are not imaged.
Who should genuinely consider one
The evidence supports whole body MRI most strongly in defined higher-risk groups rather than as universal screening.
Strong indication
- Known cancer predisposition syndromes — Li-Fraumeni, von Hippel-Lindau, hereditary paraganglioma, certain BRCA contexts where an oncologist has recommended it
- Multiple myeloma and smouldering myeloma, at diagnosis and for monitoring
- Metastatic survey in prostate, breast and other cancers where bone is the likely site
- Lymphoma staging where radiation exposure is a particular concern, especially in young patients
- Cancer of unknown primary, as part of the search
Reasonable, with informed consent
- Strong family history of cancer without an identified genetic syndrome
- Individuals who have decided on comprehensive screening and understand the incidental-finding trade-off
- Those who need repeated imaging and want to avoid cumulative radiation dose
Generally not recommended
- Average-risk asymptomatic adults expecting reassurance. The likelihood of an ambiguous finding leading to further tests substantially exceeds the likelihood of detecting a treatable early cancer.
- Anyone with a specific symptom. A targeted scan of the relevant region will always answer the question better and more cheaply.
- Patients with severe claustrophobia. This is a long scan and a difficult one to tolerate.
Whole body MRI versus PET-CT
These are often presented as competitors. They are not — they measure fundamentally different properties.
| Factor | Whole Body MRI | PET-CT |
|---|---|---|
| What it measures | Structure and water diffusion | Glucose metabolism |
| Radiation dose | None | Tracer plus CT dose |
| Injection required | Usually none | Radioactive tracer, always |
| Total time at centre | ~2 hours | ~3 hours including uptake |
| Bone marrow disease | Superior | Variable, myeloma often missed |
| Prostate bone metastases | Superior | FDG poor; PSMA PET preferred |
| Lymphoma staging | Good | Standard of care |
| Lung nodules | Poor | Good |
| Brain and liver lesions | Superior | Limited |
| Repeatability | Unlimited | Limited by cumulative dose |
For most solid tumour staging, PET-CT remains standard. For myeloma, prostate bone disease and paediatric or young-adult surveillance, whole body MRI is often the better choice. If you have a cancer diagnosis, your oncologist decides — and both are available here. See our PET-CT scan in Dehradun page for the other side of this comparison.
The incidental findings problem
This is the honest downside and the reason we insist on a conversation before booking a screening study.
Scan enough healthy people head to toe and you will find things. Simple renal cysts, liver haemangiomas, small adrenal adenomas, thyroid nodules, Tarlov cysts, benign bone islands, degenerative spine change. Across published screening series, a substantial proportion of asymptomatic participants — often around a third — have at least one finding that prompts some form of follow-up, and the overwhelming majority of those turn out to be entirely benign.
Each of those findings then carries a cost: repeat imaging in six months, a specialist consultation, occasionally a biopsy, and a period of real anxiety while it is sorted out. Some are resolved quickly. Some generate years of surveillance for something that was never going to cause harm.
None of this means whole body MRI is a bad test. It means it is a test with a real trade-off, and the decision to have one should be made with that trade-off understood rather than sold on the promise of peace of mind. Our radiologists will discuss your report with you and give a clear view on which findings genuinely warrant follow-up and which do not.
Preparing for a whole body MRI
- Fasting. Four to six hours is usual, mainly to reduce bowel motion and improve abdominal image quality. Water is fine. Take essential medication with a sip of water.
- Time. Block out around two hours. This is a long study and cannot be rushed.
- Clothing. Loose and metal-free. You will change into a gown.
- Declare. Pacemaker, defibrillator, cochlear implant, aneurysm clip, neurostimulator, insulin pump, joint replacements, plates and screws, and any history of metal fragments in the eye.
- Claustrophobia. Be realistic. If you struggle in confined spaces, this is a long time inside a bore. Tell us in advance so we can plan comfort measures, or discuss a mild sedative with your doctor.
- Bring. Any previous scans, films and CDs. Comparison changes reports more often than patients expect.
- Bladder. Empty it immediately before the scan.
What a head-to-thigh study costs locally
| Study | Indicative cost | Time |
|---|---|---|
| Whole body MRI — screening protocol | ₹18,000 – ₹24,000 {{VERIFY}} | 50–65 min |
| Whole body MRI — oncology / myeloma protocol | ₹22,000 – ₹28,000 {{VERIFY}} | 60–75 min |
| Whole body MRI + dedicated brain sequences | ₹22,000 – ₹28,000 {{VERIFY}} | 70–85 min |
| Add contrast where indicated | add ₹3,000 – ₹4,500 {{VERIFY}} | add 10–15 min |
| Add dedicated prostate mpMRI | add ₹6,000 – ₹9,000 {{VERIFY}} | add 30 min |
Full pricing detail across all modalities is on our MRI scan cost in Dehradun page.
The incidental-finding arithmetic nobody publishes
Original research
Published whole-body screening series consistently report that a substantial minority of asymptomatic participants — often around a third — finish with at least one finding that prompts follow-up, and that the overwhelming majority of those resolve as benign. {{VERIFY}}
Set against that, the yield of a genuinely treatable early cancer in an average-risk adult is low. The expected outcome of screening an average-risk person is therefore not reassurance — it is a one-in-three chance of a follow-up pathway for something that was never going to cause harm. In a defined high-risk group the same arithmetic inverts, which is why we ask about family history and genetic syndromes before booking rather than after.
Method: synthesis of published whole-body MRI screening series. Rates vary by protocol, population and radiologist threshold; treat as directional.
Which parts of Dehradun we cover
We serve the whole of Dehradun district, with complimentary pick-up and drop inside city limits. Patients travelling from Rishikesh, Haridwar, Mussoorie and Vikasnagar should mention their location when booking so we can confirm what transport is possible.
- Rajpur Road
- Dalanwala
- Clement Town
- Prem Nagar
- Vasant Vihar
- Jakhan
- Sahastradhara Road
- Race Course
- Patel Nagar
- GMS Road
- Ballupur
- Kaulagarh
- Doiwala
- Selaqui
- ISBT Dehradun
- Mussoorie
- Rishikesh
- Haridwar
- Vikasnagar
Common reference points patients use when giving directions: Clock Tower, Doon Hospital, the ISBT, Graphic Era, Max Super Speciality Hospital and Pacific Mall. If you are coming from Mussoorie, allow extra time on Rajpur Road in the afternoon.
Recommended spoke pages
Build-order recommendation from competitor internal-link anchors. Not yet written.
- Myeloma Whole Body MRI —
/myeloma-mri-dehradun/ - Cancer Screening in Dehradun —
/cancer-screening-dehradun/ - Whole Body MRI vs PET-CT —
/whole-body-mri-vs-pet-ct/
Publishing directive — Google Business Profile
Point the website field of your Google Business Profile at this page’s URL, not the site homepage. The matching service-and-city inner page is the strongest local relevance signal available, and it is wasted when GBP links to the homepage. Also list each service as a discrete GBP service item rather than burying it in the description, and set holiday hours explicitly — conversational “Ask Maps” queries are answered from structured GBP fields, not from your website.
Frequently asked questions
How much does a whole body MRI cost in Dehradun?
Typically ₹18,000 to ₹28,000, depending on protocol depth, field strength and whether contrast or additional dedicated sequences are added. Oncology protocols sit at the upper end. Confirm that films, CD and reporting are inside the quote.
How long does it take?
50 to 75 minutes of scanning across five overlapping stations. Allow around two hours at the centre once registration, safety screening and changing are included.
Is it worth doing if I feel completely well?
It depends on your risk. In average-risk adults with no family history, there is no strong evidence that whole body MRI screening reduces mortality, and a meaningful proportion of people will end up with an incidental finding that generates further tests and worry without changing anything.
In people with a known genetic cancer predisposition, or a strong family history, or an existing cancer diagnosis, it is a genuinely valuable test. We would rather have that conversation with you before you book than sell you a scan you did not need.
Whole body MRI or PET-CT?
Different tests. PET-CT measures metabolic activity and is standard for staging most solid tumours and lymphoma. Whole body MRI measures structure and diffusion with no radiation, and is better for bone marrow disease such as myeloma, for prostate bone metastases, and for brain and liver lesions. If you have a cancer diagnosis, your oncologist should choose.
Does it detect every cancer?
No. It has poor sensitivity for small lung nodules and does not reliably detect early mucosal cancers of the stomach, colon, cervix or bladder. It also does not replace mammography or a dedicated prostate MRI. Treat it as a complement to established screening programmes, never as a substitute.
Do I need contrast?
Most screening protocols do not use contrast. Diffusion-weighted imaging provides the lesion detection. Contrast is added for specific oncology questions, characterising an indeterminate lesion, or assessing treatment response.
Can I have it if I am claustrophobic?
Be honest with yourself about this — it is a long scan. Tell us in advance and we will use the shortest viable protocol, fit a mirror, provide music through headphones and allow a companion in the room where permitted. For significant claustrophobia, discuss a mild oral sedative with your referring doctor and arrange someone to drive you home.
How often can I repeat it?
There is no radiation-based limit, which is precisely the advantage. Frequency should be driven by clinical need — annually for defined high-risk surveillance, or as directed by your oncologist. Repeating a screening study yearly in an average-risk person is not evidence-based.
